PRESS RELEASE: 24 August 2022, 07:00 CEST Biocartis Obtains ISO 27001 Certification for Information Security Management Mechelen, Belgium, 24 August 2022 –…
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a…
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against…
Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 millionReduction in expenses…
Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second…
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments…
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the…
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well…
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical…
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled…